Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP19am0101090,19am0101075)
Ministry of Education, Culture, Sports, Science and Technology (18K19298)
Received: 30 September 2020
Accepted: 17 February 2021
First Online: 9 March 2021
: H.S. and J.T. are co-founders and shareholders of MiraBiologics Inc. E.M., K.S., and Ku.M. are also shareholders of the same company. All other authors declare no competing interests.